Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record.

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial

Open access
Richardson, Paul G., Soiffer, Robert J., Antin, Joseph H., Uno, Hajime, Jin, Zhezhen, Kurtzberg, Joanne, Martin, Paul L., Steinbach, Gideon, Murray, Karen F., Vogelsang, Georgia B., Chen, Allen R., Krishnan, Amrita, Kernan, Nancy A., Avigan, David E., Spitzer, Thomas R., Shulman, Howard M., Di Salvo, Donald N., Revta, Carolyn, Warren, Diane, Momtaz, Parisa, Bradwin, Gary, Wei, L.J., Iacobelli, Massimo, McDonald, George B., Guinan, Eva C.·2010·Biology of Blood and Marrow Transplantation

Abstract

Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes are dismal, but early phase I/II studies have suggested promising activity and acceptable toxicity using the novel polydisperse oligonucleotide defibrotide. This randomized phase II dose-finding trial determined the efficacy of defibrotide in patients with severe VOD following hematopoietic stem cell transplantation (HSCT) and identified an appropriate dose for future trials. Adult and pediatric patients received either lower-dose (arm A: 25 mg/kg/day; n = 75) or higher-dose (arm B: 40 mg/kg/day; n = 74) i.v. defibrotide administered in divided doses every 6 hours for > or =14 days or until complete response, VOD progression, or any unacceptable toxicity occurred. Overall complete response and day +100 post-HSCT survival rates were 46% and 42%, respectively, with no significant difference between treatment arms. The incidence of treatment-related adverse events was low (8% overall; 7% in arm A, 10% in arm B); there was no significant difference in the overall rate of adverse events between treatment arms. Early stabilization or decreased bilirubin was associated with better response and day +100 survival, and decreased plasminogen activator inhibitor type 1 (PAI-1) during treatment was associated with better outcome; changes were similar in both treatment arms. Defibrotide 25 or 40 mg/kg/day also appears effective in treating severe VOD following HSCT. In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day was selected for ongoing phase III trials in VOD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2010.02.009

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 237

Metadata

Authors
Richardson, P. G., Soiffer, R. J., Antin, J. H., Uno, H., Jin, Z., Kurtzberg, J., Martin, P. L., Steinbach, G., Murray, K. F., Vogelsang, G. B., Chen, A. R., Krishnan, A., Kernan, N. A., Avigan, D. E., Spitzer, T. R., Shulman, H. M., Di Salvo, D. N., Revta, C., Warren, D., Momtaz, P., Bradwin, G., Wei, L. J., Iacobelli, M., McDonald, G. B., & Guinan, E. C.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2010-07
Volume
16
Issue
7
Pages
1005-1017
ISSN
1083-8791 (ISSN-L)
OpenAlex
W1973519172
Cited by
237
References
0
FWCI
11.49
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. https://app.cochat.ai/papers/10.1016/j.bbmt.2010.02.009
The paper
Richardson, P. G., Soiffer, R. J., Antin, J. H., Uno, H., Jin, Z., Kurtzberg, J., Martin, P. L., Steinbach, G., Murray, K. F., Vogelsang, G. B., Chen, A. R., Krishnan, A., Kernan, N. A., Avigan, D. E., Spitzer, T. R., Shulman, H. M., Di Salvo, D. N., Revta, C., Warren, D., . . . Guinan, E. C. (2010). Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2010.02.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.